About The Peptide Doctrine
The Peptide Doctrine is an editorial publication about peptide therapy, GLP-1 medications, hormone optimization and longevity medicine in the United States. Our premise is simple: this field has more marketing than evidence, and patients deserve to know which is which before they inject anything.
What we do
- Grade every claim. Each compound profile carries an evidence table. A means strong human trials or meta-analyses; B means small or short human trials; C means observational, mechanistic or indirect human data; D means animal or in-vitro data only, or no evidence at all. The grade describes the evidence, not whether we recommend the use.
- Report doses as what was studied. We do not invent "protocols". When a dose appears, it is the dose used in a cited study or on an FDA label, and we say so. For prescribed medication, your pharmacy label overrides anything on this site.
- State the real legal status. Every compound is tagged with its FDA status, whether it sits on FDA's Category 2 list (which restricts compounding), and whether a licensed clinician can actually prescribe it in the US.
- Update when the facts change. Regulatory pages carry a "last reviewed" date and a changelog. If a study or an FDA action changes a grade, we change the page.
What we don't do
- We don't sell peptides, and we don't link to "research use only" vendors. Products sold that way are not made for human use, and we will not help route people to them.
- We don't publish before-and-after photos we can't verify, testimonials we can't attribute, or doses that have no source.
- We don't let the business side write the editorial side. See the disclosure below.
Who publishes this site
The Peptide Doctrine is published by JOINFORM, LLC, a Wyoming company based in Sheridan, WY. JOINFORM also operates Plenivida Health, a telehealth platform that connects patients with independent US-licensed clinicians for compounded GLP-1, peptide and hormone protocols.
That relationship is why this site exists: Plenivida's clinicians needed a place to send patients who asked honest questions and kept getting vendor pages back. It is also a conflict of interest, and we handle it in the open:
- Articles say when a compound is something Plenivida prescribes, and a call-to-action for Plenivida only appears on those pages.
- Competing providers are reviewed on the same criteria we would want applied to Plenivida: licensing, named pharmacy, pricing transparency, follow-up.
- Editorial decisions — what to cover, what grade a claim gets, what we say about safety — are made by the editorial team, not by Plenivida's commercial team.
How content is reviewed
Every article is researched from primary sources and goes through a clinical check before publication. Where a licensed clinician has personally reviewed an article, they are named on the page with their credentials. Read the full editorial and clinical review policy.
Contact
Corrections, study suggestions and questions: editors@peptidedoctrine.com. We answer every correction request and log the change on the page.